Intranasal INNA-051

We are conducting a study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending, intranasal INNA-051 doses in healthy adults.

We are seeking healthy males or females, between the ages of 18 to 55 years old who must be non-smokers and have a BMI of between 18 – 34.9kg/m² and a weight of > 50kg.

This study include numerous in-house stays and dosing – if you meet the criteria for this study and would like more information, register below or call 1800 727 874.